Skip to main content

Solution suite

Optum Oncology Pathways

Enhance quality and value in cancer care.

Detailed, evidence-based regimens

Enhance quality and value in cancer care when you treat patients using therapies associated with better clinical outcomes. Optum® Oncology Pathways are detailed, evidence-based regimens selected through rigorous evaluation for specific cancer types and stages. These pathways are currently used in support of 27 million members.*

Regimens are based on a comprehensive literature review of all National Comprehensive Cancer Network (NCCN) recommended regimens.

Key benefits

Selecting a regimen

Regimens are based on efficacy, safety/toxicity and drug cost. We also consider claims data for the duration of therapy, hospitalization rates and total cost of care.

Program details

Pathway selection is not needed to receive prior authorization for therapy. Our criteria for determining cancer therapies coverage will not change because of this program.

Participating physicians

Our program is not a substitute for the judgment of a physician or other healthcare professional. Care decisions are between the physician and the patient.

Experts evaluate each pathway

The Optum Oncology Advisory Committee and disease-specific expert consultants evaluate each pathway. Committee members are selected for their clinical expertise to help ensure diverse perspectives. Members include practicing medical oncologists from academic medical centers and community oncology practices who are not employed by Optum Health.

Industry insights

View all
Why Behavioral Health Plays a Critical Role in Cancer Journey

Article

Why behavioral health plays a critical role in the cancer journey

Understand how depression, anxiety, care access and treatment adherence drive higher utilization and costs for employers and payers when left unaddressed.

Integrated Cancer Care: 4 Strategies for Employers & Payers

Article

Whole-person cancer care: 4 strategies for employers and payers

Life after cancer is complex, and survivorship — living with and beyond diagnosis — demands long-term support for mental, physical and financial health.

The Cancer Data Divide: Why Integration Is the Next Frontier

Article

The cancer data divide: Why integration is the next frontier

These billion-dollar drugs are set to lose their exclusivity. But good things happen when generics and biosimilars are allowed to compete with costly brand-name drugs.

Questions about cancer pathways?

Complementary solutions

Solution suite

Transplant Solutions

Best for:
  • Payers

Get significant savings and statistically better clinical outcomes.

Solution suite

Oncology Solutions

Best for:
  • Employers
  • Payers

Our solutions address complex challenges and help manage cancer costs while improving outcomes and quality of care.

*Optum book of business 2023.